单位:[1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China[2]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[3]Harbin Med Univ, Dept Internal Med Oncol, Canc Hosp, Harbin, Peoples R China[4]Janssen China Res & Dev, Stat & Decis Sci, Shanghai, Peoples R China[5]Janssen Asia Pacific, Div Johnson & Johnson Int Singapore Pte Ltd, Singapore, Singapore
第一作者单位:[1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Shen L.,Hu G.,Wang Y.,et al.Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S347-S348.
APA:
Shen, L.,Hu, G.,Wang, Y.,Zhao, J.,Li, X....&Lu, S..(2023).Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA:
Shen, L.,et al."Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S347-S348